Insider Buying: Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Purchases $3,400,000.00 in Stock

Attovia Therapeutics, Inc. (NASDAQ:ATTO) major shareholder Redmile Group, Llc bought 200,000 shares of Attovia Therapeutics stock in a transaction dated Thursday, August 6th. The stock was purchased at an average price of $17.00 per share, with a total value of $3,400,000.00. Following the completion of the purchase, the insider owned 982,854 shares in the company, valued at $16,708,518. This trade represents a 25.55% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Redmile Group, Llc also recently made the following trade(s):

• On Thursday, August 6th, Redmile Group, Llc bought 400,000 shares of Attovia Therapeutics stock. The stock was purchased at an average cost of $17.00 per share, with a total value of $6,800,000.00.

Attovia Therapeutics Price Performance

ATTO stock opened at $18.06 on Thursday. Attovia Therapeutics, Inc. has a fifty-two week low of $16.15 and a fifty-two week high of $22.79.

Hedge Funds Weigh In On Attovia Therapeutics

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. raised its holdings in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 164,358 shares of the company’s stock after purchasing an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent SEC filing.

About Attovia Therapeutics

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.